Statement: None of the patients in cohort 1 of the primary trial had a platlet deficiency, and none of the patients in cohort 2 were constipated. 
Primary_evidence: Adverse Events 1:   Total: 17   Anaemia 2/52 (3.85%)   Febrile neutropenia 4/52 (7.69%)   Pancytopenia 1/52 (1.92%)   Thrombocytopenia 0/52 (0.00%)   Abdominal pain 1/52 (1.92%)   Constipation 1/52 (1.92%)   Pyrexia 2/52 (3.85%)   Hepatic failure 1/52 (1.92%)   Hyperbilirubinaemia 1/52 (1.92%)   Device related infection 1/52 (1.92%)   Pneumonia 2/52 (3.85%)   Sepsis 1/52 (1.92%) Adverse Events 2:   Total: 7   Anaemia 0/21 (0.00%)   Febrile neutropenia 1/21 (4.76%)   Pancytopenia 0/21 (0.00%)   Thrombocytopenia 1/21 (4.76%)   Abdominal pain 0/21 (0.00%)   Constipation 0/21 (0.00%)   Pyrexia 1/21 (4.76%)   Hepatic failure 0/21 (0.00%)   Hyperbilirubinaemia 0/21 (0.00%)   Device related infection 0/21 (0.00%)   Pneumonia 0/21 (0.00%)   Sepsis 0/21 (0.00%)